Position in ADCT
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$758,450
+$147,807 QoQ
Shares Held
202,254
+16.9% QoQ
Ownership
0.159%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Bank of New York Mellon Corp holds $1,371,862,681 across 46 Drug Manufacturers - Specialty & Generic names. ADCT ranks #36 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
3,899,720 | $460,985,889 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
329,148 | $195,178,172 | |
| 3 | VTRS |
Viatris Inc
|
14,128,917 | $190,881,662 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
702,492 | $92,546,288 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
3,809,888 | $91,170,611 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,794,432 | $54,048,287 | |
| 7 | ALKS |
Alkermes plc.
|
1,036,460 | $36,649,221 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
463,751 | $35,175,507 |
All Filings in ADCT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $758,450 | 202,254 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $610,643 | 172,987 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $634,776 | 158,694 | Shares | Defined | 2025-11-03 | |
| 2025-06-30 | $423,800 | 158,135 | Shares | Defined | 2025-08-05 | |
| 2025-03-31 | $224,845 | 159,466 | Shares | Defined | 2025-04-29 | |
| 2024-12-31 | $342,264 | 171,993 | Shares | Defined | 2025-02-04 | |
| 2024-09-30 | $511,064 | 162,243 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $648,497 | 205,221 | Shares | Defined | 2024-07-25 | |
| No filing history on record for this holder in this stock. | ||||||